Tag: GlobeNewswire

HONOLULU, Oct. 02, 2026 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its third quarter 2026 financial results on Friday, October 23, 2026 before the market opens. First Hawaiian will host a conference call to discuss the company’s results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time).

To access the call by phone, participants will need to click on the following registration link: https://register-conf.media-server.com/register/BI4e0abe37ecf34f5d8bdacfb166cade22, register for the conference call, and then you will receive the dial-in number and a personalized PIN code. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the conference call, including a slide presentation, will be available at the following link: www.fhb.com/earnings. The archive of the webcast will be available at the same location.

About First Hawaiian

First Hawaiian, Inc. (NASDAQ:FHB) is a bank holding company headquartered in Honolulu, Hawaii. Its principal subsidiary, First Hawaiian Bank, founded in 1858 under the name Bishop & Company, is Hawaii’s oldest and largest financial institution with branch locations throughout Hawaii, Guam and Saipan. The company offers a comprehensive suite of banking services to consumer and commercial customers including deposit products, loans, wealth management, insurance, trust, retirement planning, credit card and merchant processing services. Customers may also access their accounts through ATMs, online and mobile banking channels. For more information about First Hawaiian, Inc., visit www.fhb.com.

Investor Relations Contact:
Kevin Haseyama
(808) 525-6268
khaseyama@fhb.com

Media Contact:
Shari Nishijima
(808) 525-6254
snishijima@fhb.com

• The US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A is still ongoing. The FDA has not communicated a new timeline for regulatory action on the BLA 
• The FDA has informed Novo that the ongoing facility remediation activities are the cause for extension of the Agency’s review. The FDA has not identified any deficiencies related to the clinical efficacy or safety data submitted in the denecimig BLA
• Novo is actively working with the FDA, addressing the Agency’s requests for remediations related to the manufacturing facility. The extended FDA review time for the denecimig BLA has no impact on Novo’s financial outlook for 2026 and pending regulatory decision, Novo aims to launch denecimig in the US in the first half of 2027

Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA. 

Novo submitted a BLA for denecimig for the treatment of haemophilia A in adult and paediatric patients to the US FDA for review in September 2025, with an anticipated regulatory decision in the third quarter of 2026. Following this submission, the FDA performed a pre-license inspection of the manufacturing site and provided feedback. Today, the FDA has informed Novo that the ongoing facility remediation activities are the cause for extension of the Agency’s review.

“Haemophilia A patients should expect more from their standard of care,” said Mike Doustdar, president and CEO of Novo. “As Novo prepares to bring denecimig to market, our ambition is to help make better care something they can count on. Novo is already in the process of addressing the FDA’s requests as efficiently as possible and continuing to work closely with the Agency toward bringing denecimig to patients in the US.”

The Agency has not identified deficiencies related to the clinical efficacy or safety data of denecimig demonstrated in the FRONTIER clinical trial programme. Novo is continuing implementation of the facility remediation activities in response to the FDA’s feedback and is working closely with the Agency to address the outstanding requirements. The feedback on the manufacturing site does not impact other marketed Novo products.

The additional FDA review time does not have an impact on Novo’s financial outlook for 2026. Pending regulatory decision, Novo aims to launch denecimig in the US in the first half of 2027.

About the FRONTIER trials
The FRONTIER clinical programme includes FRONTIER1-5 and investigates denecimig as a prophylactic treatment to prevent bleeding episodes across paediatric and adult populations with haemophilia A, with or without inhibitors.

FRONTIER2, FRONTIER3 and FRONTIER4 formed the basis of the denecimig Marketing Authorisation Application (MAA) submission. FRONTIER2 evaluated denecimig treatment once every month and once every week in adults and adolescents 12 years of age and older; FRONTIER3 evaluated denecimig treatment once every month and once every week in children below the age of 12; FRONTIER4 was an open-label extension trial evaluating the efficacy of denecimig once every two weeks (Q2W) as well as investigating the long-term safety of denecimig across all dosing regimens (once every month, once every two weeks, and once every week) in subjects with haemophilia A, with or without inhibitors.

About denecimig
Denecimig is a FVIIIa mimetic bispecific antibody designed with the aim to deliver once monthly, every two weeks and weekly prophylaxis for people living with haemophilia A, with or without inhibitors. Denecimig, which is administered under the skin, ‘mimics’ the role of FVIIIa by bridging factor IXa and factor X. This action mimics the cofactor function of FVIIIa, which helps restore the body’s thrombin generation capacity, helping blood to clot. On 17 September, denecimig received a positive CHMP opinion and is currently pending marketing approval from the EMA and under review by other regulatory authorities.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.

Publication of inside information pursuant to Market Abuse Regulation, Article 17.

Contacts for further information

Novo Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
Novo Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com	Max Ung +45 3077 6414 mxun@novonordisk.com
Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com	Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com

Company announcement No 59 / 2026

Attachment

• 261002_Denecimig FDA

Following completion of the forensic investigation, company begins notifying impacted individuals

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (NASDAQ:IRTC) today provided an update regarding the cybersecurity incident previously disclosed in June 2026. Following completion of the forensic investigation and subsequent review to determine the nature of the impacted data, the company has begun notifying impacted individuals.

As previously disclosed, on or around June 8, 2026, iRhythm detected unauthorized access in certain third-party-hosted business applications. Upon detecting the unauthorized access, iRhythm promptly implemented its incident response plan. As part of the investigation, iRhythm has been working very closely with external cybersecurity professionals experienced in handling these types of incidents. After completing the forensic investigation, iRhythm learned certain data it stores was accessed and downloaded by unauthorized individuals between June 3 and June 8, 2026.

Following the forensic investigation, iRhythm carried out a review to determine the nature of the impacted data. This review concluded the impacted data includes: patient name; patient contact information, including address, email address, and phone number; iRhythm patient account number; iRhythm device serial number; patient insurance number; date of service; and date of birth.

iRhythm has no evidence that any personal information has been or will be used to commit identity theft. However, beginning October 2, 2026, iRhythm began notifying impacted individuals for whom it maintains contact information. Notified individuals have been provided with instructions on best practices to protect their information.

Out of an abundance of caution, those served by iRhythm are encouraged to take steps to protect themselves. This includes protecting themselves against medical identity theft and identity fraud, placing a fraud alert/security freeze on their credit files, obtaining free credit reports, and remaining vigilant in reviewing financial account statements and credit reports for fraudulent or irregular activity on a regular basis.

iRhythm has also established a call center to address questions from impacted individuals. Representatives are available from 8:00 a.m. to 8:00 p.m. Eastern time, Monday through Friday, excluding major U.S. holidays, at 1-844-770-7175.

As iRhythm previously reported, the company has not identified any impact to our products, our clinical or medical device systems, our connections to customers, our manufacturing and distribution operations, patient safety, or our ability to meet patient needs. In addition, iRhythm does not store or retain individual financial account information or payment card information. The company continues to believe, as previously stated in the Current Report on Form 8-K dated June 15, 2026, that the incident is not reasonably likely to have a material impact on the Company’s financial condition or results of operations.

iRhythm is committed to maintaining the privacy and security of personal information in its possession and has taken precautions to safeguard it. iRhythm regularly evaluates and modifies its practices and internal controls to safeguard the security and privacy of the information it maintains and is taking steps to mitigate the risk to individuals impacted by this incident.

Individuals may visit iRhythm’s website https://www.irhythmtech.com/us/en/who-we-are/news-events/notice-of-data-event to learn more about the incident and steps they can take to protect their information.

About iRhythm Holdings
iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

iRhythm Contacts

Investors	Media
Francis Pruell	Kassandra Perry
investors@irhythmtech.com	mediarelations@irhythmtech.com

Following completion of the forensic investigation, company begins notifying impacted individuals

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (NASDAQ:IRTC) today provided an update regarding the cybersecurity incident previously disclosed in June 2026. Following completion of the forensic investigation and subsequent review to determine the nature of the impacted data, the company has begun notifying impacted individuals.

As previously disclosed, on or around June 8, 2026, iRhythm detected unauthorized access in certain third-party-hosted business applications. Upon detecting the unauthorized access, iRhythm promptly implemented its incident response plan. As part of the investigation, iRhythm has been working very closely with external cybersecurity professionals experienced in handling these types of incidents. After completing the forensic investigation, iRhythm learned certain data it stores was accessed and downloaded by unauthorized individuals between June 3 and June 8, 2026.

Following the forensic investigation, iRhythm carried out a review to determine the nature of the impacted data. This review concluded the impacted data includes: patient name; patient contact information, including address, email address, and phone number; iRhythm patient account number; iRhythm device serial number; patient insurance number; date of service; and date of birth.

iRhythm has no evidence that any personal information has been or will be used to commit identity theft. However, beginning October 2, 2026, iRhythm began notifying impacted individuals for whom it maintains contact information. Notified individuals have been provided with instructions on best practices to protect their information.

Out of an abundance of caution, those served by iRhythm are encouraged to take steps to protect themselves. This includes protecting themselves against medical identity theft and identity fraud, placing a fraud alert/security freeze on their credit files, obtaining free credit reports, and remaining vigilant in reviewing financial account statements and credit reports for fraudulent or irregular activity on a regular basis.

iRhythm has also established a call center to address questions from impacted individuals. Representatives are available from 8:00 a.m. to 8:00 p.m. Eastern time, Monday through Friday, excluding major U.S. holidays, at 1-844-770-7175.

As iRhythm previously reported, the company has not identified any impact to our products, our clinical or medical device systems, our connections to customers, our manufacturing and distribution operations, patient safety, or our ability to meet patient needs. In addition, iRhythm does not store or retain individual financial account information or payment card information. The company continues to believe, as previously stated in the Current Report on Form 8-K dated June 15, 2026, that the incident is not reasonably likely to have a material impact on the Company’s financial condition or results of operations.

iRhythm is committed to maintaining the privacy and security of personal information in its possession and has taken precautions to safeguard it. iRhythm regularly evaluates and modifies its practices and internal controls to safeguard the security and privacy of the information it maintains and is taking steps to mitigate the risk to individuals impacted by this incident.

Individuals may visit iRhythm’s website https://www.irhythmtech.com/us/en/who-we-are/news-events/notice-of-data-event to learn more about the incident and steps they can take to protect their information.

About iRhythm Holdings
iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

iRhythm Contacts

Investors	Media
Francis Pruell	Kassandra Perry
investors@irhythmtech.com	mediarelations@irhythmtech.com

Following completion of the forensic investigation, company begins notifying impacted individuals

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (NASDAQ:IRTC) today provided an update regarding the cybersecurity incident previously disclosed in June 2026. Following completion of the forensic investigation and subsequent review to determine the nature of the impacted data, the company has begun notifying impacted individuals.

As previously disclosed, on or around June 8, 2026, iRhythm detected unauthorized access in certain third-party-hosted business applications. Upon detecting the unauthorized access, iRhythm promptly implemented its incident response plan. As part of the investigation, iRhythm has been working very closely with external cybersecurity professionals experienced in handling these types of incidents. After completing the forensic investigation, iRhythm learned certain data it stores was accessed and downloaded by unauthorized individuals between June 3 and June 8, 2026.

Following the forensic investigation, iRhythm carried out a review to determine the nature of the impacted data. This review concluded the impacted data includes: patient name; patient contact information, including address, email address, and phone number; iRhythm patient account number; iRhythm device serial number; patient insurance number; date of service; and date of birth.

iRhythm has no evidence that any personal information has been or will be used to commit identity theft. However, beginning October 2, 2026, iRhythm began notifying impacted individuals for whom it maintains contact information. Notified individuals have been provided with instructions on best practices to protect their information.

Out of an abundance of caution, those served by iRhythm are encouraged to take steps to protect themselves. This includes protecting themselves against medical identity theft and identity fraud, placing a fraud alert/security freeze on their credit files, obtaining free credit reports, and remaining vigilant in reviewing financial account statements and credit reports for fraudulent or irregular activity on a regular basis.

iRhythm has also established a call center to address questions from impacted individuals. Representatives are available from 8:00 a.m. to 8:00 p.m. Eastern time, Monday through Friday, excluding major U.S. holidays, at 1-844-770-7175.

As iRhythm previously reported, the company has not identified any impact to our products, our clinical or medical device systems, our connections to customers, our manufacturing and distribution operations, patient safety, or our ability to meet patient needs. In addition, iRhythm does not store or retain individual financial account information or payment card information. The company continues to believe, as previously stated in the Current Report on Form 8-K dated June 15, 2026, that the incident is not reasonably likely to have a material impact on the Company’s financial condition or results of operations.

iRhythm is committed to maintaining the privacy and security of personal information in its possession and has taken precautions to safeguard it. iRhythm regularly evaluates and modifies its practices and internal controls to safeguard the security and privacy of the information it maintains and is taking steps to mitigate the risk to individuals impacted by this incident.

Individuals may visit iRhythm’s website https://www.irhythmtech.com/us/en/who-we-are/news-events/notice-of-data-event to learn more about the incident and steps they can take to protect their information.

About iRhythm Holdings
iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

iRhythm Contacts

Investors	Media
Francis Pruell	Kassandra Perry
investors@irhythmtech.com	mediarelations@irhythmtech.com

Three-Year Vesting Ties Leadership Incentives to Long-Term Shareholder Value

TAMPA, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced that its Compensation Committee and Board of Directors approved long-term stock option awards for members of the Company’s executive leadership team and Board of Directors.

The awards granted to the Company’s Board of Directors consist of stock options to purchase 626,881 shares of the Company’s common stock each, granted on October 1, 2026 under the AtlasClear Holdings, Inc. 2024 Equity Incentive Plan, as amended, which was previously approved by the Company’s shareholders, at an exercise price of $0.2010 per share, equal to the fair market value of the common stock based on its closing price on the NYSE American on October 1, 2026, the grant date. The options vest in equal annual installments over three years, subject to continued service. The grants also include options to purchase 150,451 shares awarded to directors for service on the board of the Company’s wholly owned subsidiary AtlasClearing, Inc. (155,451 for the Chairman of the AtlasClearing board).

“Scaling a correspondent clearing platform is work measured in years rather than quarters, and stock options help align the people doing that work with our shareholders’ long-term interests,” said Craig Ridenhour, President of AtlasClear Holdings. “The three-year vesting period is designed to retain key leaders, while the opportunity to benefit from future stock price appreciation provides an incentive to execute our strategy and build long-term shareholder value.”

The stock option awards were approved by the Compensation Committee of the Company’s Board of Directors. The Company views stock options as an important part of its strategy to attract, retain and motivate experienced executives and directors as AtlasClear continues to develop and expand its financial services platform. Because the options are priced at the market on the grant date, recipients benefit only if the stock price rises.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. (NYSE American: ATCH) is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear seeks to deliver a vertically integrated suite of brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

To stay up to date on AtlasClear’s platform strategy and market perspective, subscribe to the Company’s YouTube channel and watch the Clearing the View by AtlasClear video series.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements in this communication may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions.

Forward-looking statements include, but are not limited to, statements regarding the expected retention, incentive and shareholder-alignment benefits of the stock option awards and expected future growth.

These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control, and actual results may differ materially from those anticipated. Factors that could cause actual results to differ include, but are not limited to: the Company’s failure to enter into definitive agreements with the digital asset business or the Dawson James parties, or its failure to complete the proposed acquisitions on favorable terms or at all; failure to receive the required regulatory approvals for the proposed acquisitions, including the acquisition of Commercial Bancorp of Wyoming; the Company’s inability to integrate, and to realize the benefits of, the proposed acquisitions; delays in onboarding correspondent broker-dealers or the failure of correspondent relationships to generate the anticipated revenue; changes in general economic or political conditions; changes in the markets that AtlasClear targets; slowdowns in securities or digital asset trading or shifting demand for trading, clearing and settling financial products; and any change in laws applicable to AtlasClear or any regulatory or judicial interpretation thereof. For additional information regarding risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026. AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Company Contact:
AtlasClear Holdings, Inc.
Email: AtlasClearIR@atlasclear.com

Investor Relations Contact:
Jeff Ramson, CEO
PCG Advisory, Inc.
Email: jramson@pcgadvisory.com

Three-Year Vesting Ties Leadership Incentives to Long-Term Shareholder Value

TAMPA, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced that its Compensation Committee and Board of Directors approved long-term stock option awards for members of the Company’s executive leadership team and Board of Directors.

The awards granted to the Company’s Board of Directors consist of stock options to purchase 626,881 shares of the Company’s common stock each, granted on October 1, 2026 under the AtlasClear Holdings, Inc. 2024 Equity Incentive Plan, as amended, which was previously approved by the Company’s shareholders, at an exercise price of $0.2010 per share, equal to the fair market value of the common stock based on its closing price on the NYSE American on October 1, 2026, the grant date. The options vest in equal annual installments over three years, subject to continued service. The grants also include options to purchase 150,451 shares awarded to directors for service on the board of the Company’s wholly owned subsidiary AtlasClearing, Inc. (155,451 for the Chairman of the AtlasClearing board).

“Scaling a correspondent clearing platform is work measured in years rather than quarters, and stock options help align the people doing that work with our shareholders’ long-term interests,” said Craig Ridenhour, President of AtlasClear Holdings. “The three-year vesting period is designed to retain key leaders, while the opportunity to benefit from future stock price appreciation provides an incentive to execute our strategy and build long-term shareholder value.”

The stock option awards were approved by the Compensation Committee of the Company’s Board of Directors. The Company views stock options as an important part of its strategy to attract, retain and motivate experienced executives and directors as AtlasClear continues to develop and expand its financial services platform. Because the options are priced at the market on the grant date, recipients benefit only if the stock price rises.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. (NYSE American: ATCH) is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear seeks to deliver a vertically integrated suite of brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

To stay up to date on AtlasClear’s platform strategy and market perspective, subscribe to the Company’s YouTube channel and watch the Clearing the View by AtlasClear video series.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements in this communication may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions.

Forward-looking statements include, but are not limited to, statements regarding the expected retention, incentive and shareholder-alignment benefits of the stock option awards and expected future growth.

These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control, and actual results may differ materially from those anticipated. Factors that could cause actual results to differ include, but are not limited to: the Company’s failure to enter into definitive agreements with the digital asset business or the Dawson James parties, or its failure to complete the proposed acquisitions on favorable terms or at all; failure to receive the required regulatory approvals for the proposed acquisitions, including the acquisition of Commercial Bancorp of Wyoming; the Company’s inability to integrate, and to realize the benefits of, the proposed acquisitions; delays in onboarding correspondent broker-dealers or the failure of correspondent relationships to generate the anticipated revenue; changes in general economic or political conditions; changes in the markets that AtlasClear targets; slowdowns in securities or digital asset trading or shifting demand for trading, clearing and settling financial products; and any change in laws applicable to AtlasClear or any regulatory or judicial interpretation thereof. For additional information regarding risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026. AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Company Contact:
AtlasClear Holdings, Inc.
Email: AtlasClearIR@atlasclear.com

Investor Relations Contact:
Jeff Ramson, CEO
PCG Advisory, Inc.
Email: jramson@pcgadvisory.com

Three-Year Vesting Ties Leadership Incentives to Long-Term Shareholder Value

TAMPA, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced that its Compensation Committee and Board of Directors approved long-term stock option awards for members of the Company’s executive leadership team and Board of Directors.

The awards granted to the Company’s Board of Directors consist of stock options to purchase 626,881 shares of the Company’s common stock each, granted on October 1, 2026 under the AtlasClear Holdings, Inc. 2024 Equity Incentive Plan, as amended, which was previously approved by the Company’s shareholders, at an exercise price of $0.2010 per share, equal to the fair market value of the common stock based on its closing price on the NYSE American on October 1, 2026, the grant date. The options vest in equal annual installments over three years, subject to continued service. The grants also include options to purchase 150,451 shares awarded to directors for service on the board of the Company’s wholly owned subsidiary AtlasClearing, Inc. (155,451 for the Chairman of the AtlasClearing board).

“Scaling a correspondent clearing platform is work measured in years rather than quarters, and stock options help align the people doing that work with our shareholders’ long-term interests,” said Craig Ridenhour, President of AtlasClear Holdings. “The three-year vesting period is designed to retain key leaders, while the opportunity to benefit from future stock price appreciation provides an incentive to execute our strategy and build long-term shareholder value.”

The stock option awards were approved by the Compensation Committee of the Company’s Board of Directors. The Company views stock options as an important part of its strategy to attract, retain and motivate experienced executives and directors as AtlasClear continues to develop and expand its financial services platform. Because the options are priced at the market on the grant date, recipients benefit only if the stock price rises.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. (NYSE American: ATCH) is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear seeks to deliver a vertically integrated suite of brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

To stay up to date on AtlasClear’s platform strategy and market perspective, subscribe to the Company’s YouTube channel and watch the Clearing the View by AtlasClear video series.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements in this communication may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions.

Forward-looking statements include, but are not limited to, statements regarding the expected retention, incentive and shareholder-alignment benefits of the stock option awards and expected future growth.

These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control, and actual results may differ materially from those anticipated. Factors that could cause actual results to differ include, but are not limited to: the Company’s failure to enter into definitive agreements with the digital asset business or the Dawson James parties, or its failure to complete the proposed acquisitions on favorable terms or at all; failure to receive the required regulatory approvals for the proposed acquisitions, including the acquisition of Commercial Bancorp of Wyoming; the Company’s inability to integrate, and to realize the benefits of, the proposed acquisitions; delays in onboarding correspondent broker-dealers or the failure of correspondent relationships to generate the anticipated revenue; changes in general economic or political conditions; changes in the markets that AtlasClear targets; slowdowns in securities or digital asset trading or shifting demand for trading, clearing and settling financial products; and any change in laws applicable to AtlasClear or any regulatory or judicial interpretation thereof. For additional information regarding risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026. AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Company Contact:
AtlasClear Holdings, Inc.
Email: AtlasClearIR@atlasclear.com

Investor Relations Contact:
Jeff Ramson, CEO
PCG Advisory, Inc.
Email: jramson@pcgadvisory.com

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company’s newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D.

The stock options have an exercise price of $8.91 per share, which is equal to the closing price of the company’s common stock on October 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following the applicable employee’s commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to such employee’s continued service with the company or any of its subsidiaries through each applicable vesting date.

The stock options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreements covering the grants and were made as an inducement material to the applicable employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

Investor Contact
Alex Lobo, Precision AQ
Alex.lobo@precisionaq.com

Media Contact
Josie Butler, 1AB
josie@1abmedia.com

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company’s newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D.

The stock options have an exercise price of $8.91 per share, which is equal to the closing price of the company’s common stock on October 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following the applicable employee’s commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to such employee’s continued service with the company or any of its subsidiaries through each applicable vesting date.

The stock options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreements covering the grants and were made as an inducement material to the applicable employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

Investor Contact
Alex Lobo, Precision AQ
Alex.lobo@precisionaq.com

Media Contact
Josie Butler, 1AB
josie@1abmedia.com